Heron Therapeutics is soaring following its impressive Q4 adjusted EPS results and optimistic FY24 revenue guidance. Investors are showing increased confidence in the company’s earnings potential, resulting in a Zacks Rank #1 (Strong Buy) upgrade. The stock price of Heron Therapeutics (HRTX) has been on the rise, reflecting a positive market sentiment towards its future prospects. Analysts are bullish on Heron Therapeutics, with a consensus rating of buy and price targets indicating a potential increase in value. The company’s recent performance has seen a surge in stock price and market cap, with analysts forecasting a significant upside from the current price. Heron Therapeutics’ 52-week high stands at $2.99, while the low is $0.50.
HRTX Stock Fluctuates on March 12, 2024: Analysis and Insights
On March 12, 2024, HRTX stock experienced some fluctuations in its performance. According to data from CNN Money, the stock closed at $2.36, marking a decrease of $0.05 or 2.07% from the previous market close. Despite this drop, HRTX is still trading in the middle of its 52-week range and above its 200-day simple moving average.
After the market closed, HRTX saw a slight increase in its stock price during after-hours trading, rising by $0.21. This uptick in price could be attributed to various factors such as positive news, investor sentiment, or market speculation. It is important to note that after-hours trading can be more volatile and less liquid than regular trading hours.
Overall, HRTX’s performance on March 12th showcased some volatility with a slight decrease during regular trading hours followed by a modest increase in after-hours trading. Investors should continue to monitor the stock’s performance and stay informed about any developments that may impact its price in the future.
Heron Therapeutics Inc. (HRTX) Shows Positive Growth in Revenue, Net Income, and EPS in Financial Results Report for 2024
On March 12, 2024, investors and analysts closely watched the performance of Heron Therapeutics Inc. (HRTX) stock as the company released its financial results for the past year and the third quarter. According to the data, sourced from CNN Money, Heron Therapeutics reported total revenue of $107.67 million for the past year, representing a 24.7% increase compared to the previous year. The total revenue remained flat at $31.43 million for the third quarter compared to the previous quarter. In terms of net income, Heron Therapeutics reported a net loss of $182.02 million for the past year, which was an improvement of 17.52% compared to the previous year. The net loss for the third quarter was $25.01 million, showing a significant improvement of 40.54% compared to the previous quarter. Earnings per share (EPS) also showed positive trends for Heron Therapeutics. The company reported an EPS of -$1.67 for the past year, which was an improvement of 25.4% compared to the previous year. The EPS for the third quarter was -$0.17, showing a substantial improvement of 50.9% compared to the previous quarter. Overall, the data indicates that Heron Therapeutics has been making progress in terms of revenue growth, net income, and earnings per share. Investors and analysts will be keeping a close eye on Heron Therapeutics stock to see how the company continues to perform in the coming quarters.
